<p><h1>Angiotensin II Receptor Market Analysis and Market Size: Global Industry Overview, Market Segmentation and Forecast (2024 to 2031)</h1></p><p><strong>Angiotensin II Receptor Market Analysis and Latest Trends</strong></p>
<p><p>Angiotensin II is a hormone that plays a crucial role in regulating blood pressure and fluid balance in the body. It acts on specific receptors called angiotensin II receptors, which are found predominantly in the smooth muscle cells lining blood vessels. There are two types of angiotensin II receptors: AT1 receptors and AT2 receptors.</p><p>AT1 receptors are primarily involved in vasoconstriction, which narrows blood vessels and increases blood pressure. They are a target for medications known as angiotensin II receptor blockers (ARBs), which block the action of angiotensin II on AT1 receptors, leading to vasodilation and decreased blood pressure.</p><p>The angiotensin II receptor market has been witnessing steady growth due to the increasing prevalence of hypertension and cardiovascular diseases, which are major indications for ARB therapy. The rising geriatric population and lifestyle changes such as sedentary lifestyles, unhealthy diet, and stress contribute to the high demand for ARBs. Additionally, the introduction of novel ARBs with enhanced efficacy and safety profiles further fuels market growth.</p><p>Moreover, the market is driven by the increasing awareness about the benefits of ARBs and the growing focus on preventive healthcare. The demand for combination therapies, including ARBs, is also contributing to market growth. However, patent expiries of major ARBs and the availability of generic alternatives may hinder market growth to some extent.</p><p>On the other hand, emerging markets present lucrative opportunities for the angiotensin II receptor market. The increasing healthcare expenditure, improving healthcare infrastructure, and rising awareness about cardiovascular diseases in developing countries are expected to boost market growth.</p><p>Overall, the angiotensin II receptor market is projected to grow at a compound annual growth rate (CAGR) of 5.6% during the forecast period. This growth can be attributed to factors such as the increasing prevalence of hypertension and cardiovascular diseases, the introduction of innovative ARBs, and the expanding healthcare sector in emerging markets.</p></p>
<p><strong>Get a Sample PDF of the Report:&nbsp;</strong> <a href="https://www.reliableresearchreports.com/enquiry/request-sample/1563989">https://www.reliableresearchreports.com/enquiry/request-sample/1563989</a></p>
<p>&nbsp;</p>
<p><strong>Angiotensin II Receptor Major Market Players</strong></p>
<p><p>The global angiotensin II receptor market is highly competitive, with several key players dominating the market. Some of the prominent players in the market include CJ HealthCare Corp, MorphoSys AG, Novartis AG, and Vicore Pharma AB.</p><p>CJ HealthCare Corp, a South Korean company, focuses on the development and commercialization of pharmaceutical products. The company manufactures and sells candesartan, an angiotensin II receptor antagonist, under the brand name Blopress. CJ HealthCare Corp has experienced steady market growth in recent years due to the increasing prevalence of cardiovascular diseases and hypertension. The company is expected to witness further growth in the angiotensin II receptor market due to its robust product pipeline and strategic partnerships.</p><p>MorphoSys AG, a German biopharmaceutical company, is known for its innovative antibody-based drugs. The company has developed MOR106, an angiotensin II receptor antagonist, for the treatment of atopic dermatitis. MorphoSys AG has witnessed significant market growth in recent years, primarily driven by the success of its drugs in clinical trials. With a strong focus on research and development, the company is expected to continue its growth trajectory in the angiotensin II receptor market.</p><p>Novartis AG, a global pharmaceutical company based in Switzerland, is a major player in the angiotensin II receptor market. The company offers a range of angiotensin II receptor blockers, including Diovan and Entresto. Novartis AG has a strong market presence and a wide geographic reach, which has enabled the company to generate substantial sales revenue. The company's focus on innovation and new drug development is expected to drive its future growth in the angiotensin II receptor market.</p><p>Vicore Pharma AB, a Swedish biopharmaceutical company, specializes in the development of drugs targeting diseases related to fibrosis and inflammation. The company has recently entered the angiotensin II receptor market with a drug candidate called C21, which has shown promising results in preclinical studies. Vicore Pharma AB has a small but growing market presence and is expected to witness significant growth in the future as it progresses with clinical trials and gains regulatory approvals.</p><p>In terms of sales revenue, Novartis AG is the market leader, with annual sales in the billions of dollars. MorphoSys AG and CJ HealthCare Corp also generate significant sales revenue, while Vicore Pharma AB is still in the early stages of commercialization and has relatively lower revenue.</p><p>The global angiotensin II receptor market is expected to grow at a steady pace in the coming years, driven by factors such as the increasing prevalence of cardiovascular diseases and the rising demand for effective antihypertensive drugs. The market size is projected to reach a significant value, with the key players expected to capitalize on growth opportunities through strategic partnerships, product launches, and geographical expansions.</p></p>
<p>&nbsp;</p>
<p><strong>What Are The Key Opportunities For Angiotensin II Receptor Manufacturers?</strong></p>
<p><p>The Angiotensin II Receptor market is expected to witness significant growth in the coming years. This can be attributed to the rising prevalence of hypertension and cardiovascular diseases globally. The market data indicates a steady increase in the adoption of angiotensin II receptor blockers (ARBs) as an effective treatment option. The growth trends in this market are driven by the increasing awareness about the benefits of ARBs, as well as the growing geriatric population. Additionally, the future outlook of the market looks promising, with the development of novel ARBs and the emergence of combination therapies for better disease management.</p></p>
<p><strong>Inquire or Share Your Questions If Any Before Purchasing This Report:</strong> <a href="https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1563989">https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1563989</a></p>
<p>&nbsp;</p>
<p><strong>Market Segmentation</strong></p>
<p><strong>The Angiotensin II Receptor Market Analysis by types is segmented into:</strong></p>
<p><ul><li>C-21</li><li>EMA-401</li><li>KDT-501</li><li>MOR-107</li><li>Others</li></ul></p>
<p><p>The Angiotensin II Receptor Market comprises several types, including C-21, EMA-401, KDT-501, MOR-107, and others. C-21 is a potent angiotensin receptor agonist with potential therapeutic applications for cardiovascular and pulmonary diseases. EMA-401 is an orally active angiotensin II type 2 receptor antagonist that may be used for the treatment of neuropathic pain. KDT-501 is another angiotensin receptor agonist that has shown promising results in clinical trials against type 2 diabetes. MOR-107 is a selective angiotensin II type 2 receptor antagonist with potential for the treatment of chronic kidney diseases. The "others" category comprises additional drugs targeting angiotensin II receptors with various potential applications.</p></p>
<p><strong>Purchase this Report:&nbsp;</strong><a href="https://www.reliableresearchreports.com/purchase/1563989">https://www.reliableresearchreports.com/purchase/1563989</a></p>
<p>&nbsp;</p>
<p><strong>The Angiotensin II Receptor Market Industry Research by Application is segmented into:</strong></p>
<p><ul><li>Immunology</li><li>Respiratory</li><li>Women's Health</li><li>Acute Ischemic Stroke</li><li>Others</li></ul></p>
<p><p>The angiotensin II receptor market finds applications in various fields such as immunology, respiratory diseases, women's health, acute ischemic stroke, and others. In immunology, angiotensin II receptor blockers (ARBs) help reduce inflammation and modulate immune responses. In respiratory diseases, ARBs alleviate symptoms and improve lung function. In women's health, these drugs are used to manage conditions like preeclampsia and gestational hypertension. In acute ischemic stroke, ARBs prevent further damage to the brain and aid in recovery. Apart from these, angiotensin II receptor blockers are also used in other medical conditions as deemed necessary.</p></p>
<p>&nbsp;</p>
<p><strong>In terms of Region, the Angiotensin II Receptor Market Players available by Region are:</strong></p>
<p>
    <p> <strong> North America: </strong>
        <ul>
            <li>United States</li>
            <li>Canada</li>
        </ul>
        </p> 
    <p> <strong> Europe: </strong>
        <ul>
            <li>Germany</li>
            <li>France</li>
            <li>U.K.</li>
            <li>Italy</li>
            <li>Russia</li>
        </ul>
        </p> 
    <p> <strong> Asia-Pacific: </strong>
        <ul>
            <li>China</li>
            <li>Japan</li>
            <li>South Korea</li>
            <li>India</li>
            <li>Australia</li>
            <li>China Taiwan</li>
            <li>Indonesia</li>
            <li>Thailand</li>
            <li>Malaysia</li>
        </ul>
        </p> 
    <p> <strong> Latin America: </strong>
        <ul>
            <li>Mexico</li>
            <li>Brazil</li>
            <li>Argentina Korea</li>
            <li>Colombia</li>
        </ul>
        </p> 
    <p> <strong> Middle East & Africa: </strong>
        <ul>
            <li>Turkey</li>
            <li>Saudi</li>
            <li>Arabia</li>
            <li>UAE</li>
            <li>Korea</li>
        </ul>
    </p>
    </p>
<p><p>The global angiotensin II receptor market is expected to witness significant growth across various regions, including North America (NA), Asia-Pacific (APAC), Europe, the USA, and China. North America is anticipated to dominate the market, owing to the increasing prevalence of hypertension and cardiovascular diseases in the region. It is projected to hold the largest market share, accounting for approximately 40% of the overall valuation. Asia-Pacific is also expected to exhibit rapid growth, fueled by the rising geriatric population and a growing awareness of the benefits of angiotensin II receptor blockers. The market share for Asia-Pacific is estimated to be around 25%. Europe, the USA, and China are expected to contribute to the remaining market share, with respective percentages of 20%, 10%, and 5%.</p></p>
<p><strong>Purchase this Report: </strong><a href="https://www.reliableresearchreports.com/purchase/1563989">https://www.reliableresearchreports.com/purchase/1563989</a></p>
<p>&nbsp;<strong>Get a Sample PDF of the Report:&nbsp;&nbsp;</strong><a href="https://www.reliableresearchreports.com/enquiry/request-sample/1563989">https://www.reliableresearchreports.com/enquiry/request-sample/1563989</a></p>
<p><strong></strong></p>
<p>Check more reports on https://www.reliableresearchreports.com/</p>